Globally, a reduced positive predictive value (PPV) of approximately 58% (95% CI: 49%–66%) was observed [PPVt(15;17)AML: 94% (95% CI: 68%–99%); PPVKMT2A(MLL)AML: 47% (95% CI: 30%–64%); PPVt(8;21)AML: 44% (95% CI: 29%–59%), and PPV(inv16)/t(16;16)AML: 40% (95% CI: 21%–62%)]. The gene discussed is KMT2A; the disease is acute myeloid leukemia.